(Fort Worth, TX, USA) — DFB Pharmaceuticals affiliate HEALTHPOINT®, Ltd., a Texas-based market leader in tissue management, dermatology, and surgical products, has signed an agreement with Italy-based HT Group to market OASIS® Wound Matrix and OASIS® Burn Matrix.

         OASIS is a natural, extracellular matrix---a biomaterial used to manage a variety of wounds by providing an environment that allows a patient’s body to rebuild and repair damaged tissue. OASIS can be used in the management of partial and full-thickness wounds, such as pressure, venous, and chronic vascular ulcers, diabetic ulcers, surgical and trauma wounds, second-degree burns, abrasions, and autograft donor sites.

         The agreement grants HT Group distribution rights for OASIS products in Italy. Discussions for marketing of other HEALTHPOINT products are currently in progress.

         “HT Group’s knowledge of the Italian healthcare market and its training programs for sales representatives and customers make it well placed for success with OASIS.” said Jay Nisbet, Senior Director, International Business Development for HEALTHPOINT. “This agreement establishes a firm foundation for HEALTHPOINT to build its product line in Italy.”

         HT Group promotes and markets surgical and dermatological products and equipment. The company, which offers an integrated approach to healthcare marketing and biotechnologies, consists of a marketing division devoted to training and educating healthcare professionals, a sales division designed to serve both the public and private sectors, and a biotech division providing support and advice to leading international manufacturers of biotechnological and biomedical products.

         “HT Group is pleased to be HEALTHPOINT’s distributor,” said Dr. Giuseppe Mucci, CEO of HT Group. “We believe there is significant market potential for these wound and burn matrices and look forward to developing OASIS in the Italian healthcare market.”

         Cook Biotech Incorporated is the manufacturer of OASIS and holds the required regulatory approvals in the European Union (CE Mark). HEALTHPOINT initially marketed OASIS in the U.S. and extended marketing efforts internationally beginning with Canada in late 2002, and Mexico in early 2004. OASIS Burn Matrix, a product that provides a supportive environment in the management of second-degree and superficial burns, was designed specifically for burn patients. The thickness of the OASIS Burn Matrix allows application for an extended time. This decreases the frequency of dressing changes, which are often exceptionally painful for burn patients.

         Since its inception in 1992, HEALTHPOINT Ltd., a DFB Pharmaceuticals, Inc. affiliate company, has established a strong domestic U.S. presence in the research, development, and marketing of branded pharmaceuticals, over the counter drugs, and medical devices for the tissue management, dermatology, and surgical fields. An aggressive research and development effort has taken unique technologies to the market, setting the pace for a highly trained field sales organization that is expanding across North America and beyond. HEALTHPOINT is based in Fort Worth, Texas, USA with additional offices in Canada. Visit HEALTHPOINT’s website at www.healthpoint.com.

         Also headquartered in Fort Worth, DFB provides technology-driven products, outsourcing services, and licensing opportunities for the healthcare industry worldwide through its affiliate companies, contract partners, and branded marketing organizations.

         COOK Biotech Incorporated (www.cookbiotech.com), located in West Lafayette, Indiana, USA, was established in 1995 to research, develop and manufacture products based on extracellular matrix (ECM) technology. COOK Biotech is actively developing ECM and scaffold-based biomaterials for numerous medical purposes. Medical products utilizing COOK’s patented ECM Technology are currently marketed worldwide for use in wound management and surgical repair of soft tissue. Together with a network of medical practitioners, COOK Biotech is identifying the medical needs most compatible with ECM technology and developing products to meet these needs.

###